BioSci – Top12_IO_Targets_Final
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
diseasemoa categorycompoundidcompound namemolecular targettarget actiontechnologydealiddeal subject
2
CancerImmuno-Oncology1354ONT-10, BGLP-40, L-BGLP40(null)(null)Monoclonals2838Phase I evaluation of ONT-10 combined with varlilumab for breast and ovarian cancer
3
CancerImmuno-Oncology1357AST-VAC2, GRNVAC 2(null)(null)
Cell Therapy - Stem Cells/Factors
3692Clinical Development Partnership to advance AST-VAC2 allogeneic vaccine for lung cancer
4
CancerImmuno-Oncology1359Avicine, CTP 37(null)(null)Peptides3781Avicine cancer vaccine in US
5
CancerImmuno-Oncology1348Melacine(null)(null)Vaccines3915Melacine therapeutic vaccine for treatment of melanoma
6
CancerImmuno-Oncology1389Canvaxin, C-VAX(null)(null)
Immunoglobulin
4784Canvaxin for advanced melanoma
7
CancerImmuno-Oncology1349tecemotide(null)(null)Vaccines6928Tecemotide (Stimuvax BLP25 liposomal vaccine) and Theratope vacccine for cancer
8
CancerImmuno-Oncology1389Canvaxin, C-VAX(null)(null)
Cell Therapy - Stem Cells/Factors
9092Autologous cell melanoma cancer vaccine
9
CancerImmuno-Oncology1333WO-12(null)(null)Vaccines9403WO-12 oncolytic virus immunotherapy cancer vaccine
10
CancerImmuno-Oncology889Tovax5T4(null)Vaccines2147Tovax (5T4 gene antigen immunotherapy) renal & colorectal cancer vaccine
11
CancerImmuno-Oncology281GI-10000BCR-ABL tyrosine kinase(null)Peptides2569Options to GI-4000 (Ras), GI-6300 (CEA), GI-3000 (EGFR) & GI-10000 (Bcr-Abl) oncology programs
12
Autoimmune/Inflammatory
Immuno-Oncology864Arzerra, ofatumumab, HuMax-CD20B-lymphocyte antigen CD20InhibitorMonoclonals2494Arzerra (HuMax-CD20 ofatumumab) for leukemia, lymphoma and rheumatoid arthritis
13
Autoimmune/Inflammatory
Immuno-Oncology864Arzerra, ofatumumab, HuMax-CD20B-lymphocyte antigen CD20InhibitorMonoclonals6364Ofatumumab anti-CD20 mAb for non-oncology indications
14
CancerImmuno-Oncology864Arzerra, ofatumumab, HuMax-CD20B-lymphocyte antigen CD20InhibitorMonoclonals4120Transfer of Arzerra (ofatumumab) for cancer indications
15
CancerImmuno-Oncology1293GI-6301brachyury(null)Peptides2569Options to GI-4000 (Ras), GI-6300 (CEA), GI-3000 (EGFR) & GI-10000 (Bcr-Abl) oncology programs
16
CancerImmuno-Oncology1293GI-6301brachyury(null)Vaccines4923G1-6300 Tarmogen program (targeting brachyury protein) for cancer
17
CancerImmuno-Oncology1293GI-6301brachyury(null)Vaccines11593GI-4000, GI-6207, GI-6301 and GI-6100 immunotherapy vaccine programs for cancer
18
Autoimmune/Inflammatory
Immuno-Oncology1301OvaRex, oregovomab, B43.13CA125 ovarian cancer antigen (MUC16)(null)Monoclonals3671OvaReX, BrevaReX, ProstaRex, AR54 and GivaRex therapeutic antibodies ex-Europe & Mideast
19
CancerImmuno-Oncology1301OvaRex, oregovomab, B43.13CA125 ovarian cancer antigen (MUC16)(null)Vaccines3049OvaRex monoclonal antibody for ovarian and other cancer
20
CancerImmuno-Oncology1301OvaRex, oregovomab, B43.13CA125 ovarian cancer antigen (MUC16)(null)Monoclonals7405OvaRex MAb for ovarian cancer in UK, France and other Europe
21
CancerImmuno-Oncology1301OvaRex, oregovomab, B43.13CA125 ovarian cancer antigen (MUC16)(null)Monoclonals7406OvaRex, BrevaRex, GivaRex and ProstaRex MAb compounds for cancer in Europe & Mideast
22
CancerImmuno-Oncology280GI-6300carcinoembryonic antigen (CEA)(null)Peptides2569Options to GI-4000 (Ras), GI-6300 (CEA), GI-3000 (EGFR) & GI-10000 (Bcr-Abl) oncology programs
23
CancerImmuno-Oncology280GI-6300carcinoembryonic antigen (CEA)(null)Vaccines4923G1-6300 Tarmogen program (targeting brachyury protein) for cancer
24
CancerImmuno-Oncology1292GI-6207carcinoembryonic antigen (CEA)(null)Vaccines4927GI-6207 targeting carcinoembryonic antigen (CEA) for cancer
25
CancerImmuno-Oncology1292GI-6207carcinoembryonic antigen (CEA)(null)Vaccines11593GI-4000, GI-6207, GI-6301 and GI-6100 immunotherapy vaccine programs for cancer
26
AllergicImmuno-Oncology673Poteligeo, mogamulizumab, KW-0761, AMG 761CC chemokine receptor type 4 (CCR4) (CD194)(null)Monoclonals2606Mogamulizumab (KW-0761) anti-CCR4 humanized MAb for inflammation ex-Japan, China, Korea
27
CancerImmuno-Oncology673Poteligeo, mogamulizumab, KW-0761, AMG 761CC chemokine receptor type 4 (CCR4) (CD194)(null)Monoclonals3376Phase I evaluation of MEDI4736/mogamulizumab and tremelimumab/mogamulizumab
28
CancerImmuno-Oncology673Poteligeo, mogamulizumab, KW-0761, AMG 761CC chemokine receptor type 4 (CCR4) (CD194)(null)Monoclonals3744Phase I study of PF-05082566 with Poteligeo (mogamulizumab) for solid tumors
29
CancerImmuno-Oncology673Poteligeo, mogamulizumab, KW-0761, AMG 761CC chemokine receptor type 4 (CCR4) (CD194)(null)Monoclonals4091Phase I study of Opdivo (nivolumab) combined with mogamulizumab for solid tumors
30
CancerImmuno-Oncology503rocapuldencel-T, AGS-003CD154 (CD40L)Inhibitor
Cell Therapy - Stem Cells/Factors
1208AGS-003 personalized dendritic cell immunotherapy for mRCC in Russia
31
CancerImmuno-Oncology503rocapuldencel-T, AGS-003CD154 (CD40L)InhibitorVaccines5142AGS-003 dendritic cell immunotherapy for cancer in China
32
CancerImmuno-Oncology1346CD40LGVAX, GM-CSF/CD40LCD154 (CD40L)StimulantVaccines5556CD40LGVAX vaccine and related technologies for lung cancer
33
CancerImmuno-Oncology503rocapuldencel-T, AGS-003CD154 (CD40L)Inhibitor
Cell Therapy - Stem Cells/Factors
6773AGS-003 dendritic cell immunotherapy for mRCC in Korea
34
CancerImmuno-Oncology503rocapuldencel-T, AGS-003CD154 (CD40L)Inhibitor
Cell Therapy - Stem Cells/Factors
6851AGS003 immunotherapy product for metastatic renal cell cancer in Japan
35
CancerImmuno-Oncology503rocapuldencel-T, AGS-003CD154 (CD40L)InhibitorGenomics9272immunoSEQ immune profiling platform to characterize patient response to AGS-003 and AGS-004
36
CancerImmuno-Oncology183MOR208, XmAb5574CD19(null)Monoclonals1370MOR208 (XmAb5574 humanized anti-CD19 MAb) for B-cell malignancies
37
CancerImmuno-Oncology33duvortuxizumab, MGD011, JNJ-64052781CD19, CD3InhibitorMonoclonals4195Duvortuxizumab (MGD011 humanized CD19 /CD3) for multiple B-cell malignancies
38
Autoimmune/Inflammatory
Immuno-Oncology154Rituxin, MabThera, rituximab, R105, RG105, IDEC-C2B8, JHL1101CD20InhibitorMonoclonals1258Etanercept and rituximab biosimilars in Japan, South Korea and Taiwan
39
Autoimmune/Inflammatory
Immuno-Oncology154Rituxin, MabThera, rituximab, R105, RG105, IDEC-C2B8, JHL1101CD20InhibitorMonoclonals2959Bulk supply of Rituxan (anti-CD20)
40
Autoimmune/Inflammatory
Immuno-Oncology154Rituxin, MabThera, rituximab, R105, RG105, IDEC-C2B8, JHL1101CD20InhibitorMonoclonals4969Rituxin (rituximab chimeric CD20 MAb) for non-Hodgkin's lymphoma and RA
41
Autoimmune/Inflammatory
Immuno-Oncology393ublituximab, TGTX1101CD20(null)Monoclonals6479TG-1101 (ublituximab chimeric MAb to CD20) for leukemia and autoimmune disorders
42
Autoimmune/Inflammatory
Immuno-Oncology393ublituximab, TGTX1101CD20(null)Monoclonals6623Ublituximab (TGTX­1101 anti-CD20 antibody) for cancer & autoimmune in S Korea and ASEAN
43
CancerImmuno-Oncology83Bexxar, tositumomabCD20InhibitorMonoclonals35BEXXAR (tositumomab) for cancer in Europe
44
CancerImmuno-Oncology83Bexxar, tositumomabCD20InhibitorMonoclonals36ZEVALIN/BEXXAR patent settlement
45
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals36ZEVALIN/BEXXAR patent settlement
46
CancerImmuno-Oncology83Bexxar, tositumomabCD20InhibitorMonoclonals49Bexxar (anti-CD20 MAb) for non-Hodgkin's lymphoma ex-Japan
47
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals71Zevalin (anti-CD20 yttrium-90 MAb conjugate) for non-Hodgkin's lymphoma ex-US
48
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals1715Zevalin (ibritumomab tiuxetan) radioimmunotherapy for non-Hodgkin’s lymphoma in US
49
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals1716RIT Oncology JV to market ZEV ALIN (lbritumomab Tiuxetan) in US
50
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20Inhibitor
Immunoglobulin
2815Zevalin (ibritumomab tiuxetan) IP for non-Hodgkin’s lymphoma
51
CancerImmuno-Oncology83Bexxar, tositumomabCD20InhibitorMonoclonals2891Bexxar (tositumobab) for non-Hodgkin's lymphoma
52
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorDrug Delivery4774Zevalin (ibritumomab tiuxetan), Marqibo (vincristine sulfate) and Melphalan in China
53
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals6478ZEVALIN (ibritumomab tiuxetan) injection for non-Hodgkin's lymphoma ex-US
54
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals7426Zevalin (ibritumomab tiuxetan) for lymphoma in Japan, Middle East, Africa & Latin America
55
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals7843Zevalin, Folotyn, Beleodaq and Marqibo hemato-oncology products in Canada
56
CancerImmuno-Oncology154Rituxin, MabThera, rituximab, R105, RG105, IDEC-C2B8, JHL1101CD20InhibitorMonoclonals8125Biosimilar rituximab for hematologic cancer in Japan
57
CancerImmuno-Oncology542Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab, CT-P10CD20InhibitorMonoclonals8125Biosimilar rituximab for hematologic cancer in Japan
58
CancerImmuno-Oncology87Zevalin, ibritumomab tiuxetan, IDEC-Y2B8CD20InhibitorMonoclonals8889Zevalin (ibritumomab tiuxetan) for lymphoma in India
59
CancerImmuno-Oncology542Blitzima, Ritemvia, Truxima, Tuxella, biosimilar rituximab, CT-P10CD20InhibitorMonoclonals9685CT-P10 and CT-P6 biosimilars for cancer in the US and Canada
60
CancerImmuno-Oncology154Rituxin, MabThera, rituximab, R105, RG105, IDEC-C2B8, JHL1101CD20InhibitorMonoclonals9787Mabion CD20 (mabthera/rituximab biosimilar) in EU
61
CancerImmuno-Oncology154Rituxin, MabThera, rituximab, R105, RG105, IDEC-C2B8, JHL1101CD20InhibitorMonoclonals9870Rituximab (JHL1101) biosimilar and option to additional compounds in China
62
CancerImmuno-Oncology54XmAb 13676CD20, CD3(null)Monoclonals9173XmAb 14045 (CD123/CD3) and XmAb 13676 (CD20/CD3 bispecific Fc MAb) ex-US
63
Autoimmune/Inflammatory
Immuno-Oncology214epratuzumab, IMMU-103CD22(null)Monoclonals1532Epratuzumab (IMMU-103) humanized anti-CD22 monoclonal antibody for autoimmune diseases
64
CancerImmuno-Oncology214epratuzumab, IMMU-103CD22(null)Monoclonals1527Epratuzumab humanized anti-CD22 monoclonal antibody for non-Hodgkin's lymphoma in NA & Australia
65
CancerImmuno-Oncology214epratuzumab, IMMU-103CD22(null)Monoclonals1536Evaluation of epratuzumab (hu CD-22 Ab) conjugated to thorium-227 for cancer
66
CancerImmuno-Oncology565CD22-4AP, TRPH-222CD22(null)Monoclonals9826CD22-4AP antibody-drug conjugate for cancer
67
CancerImmuno-Oncology565CD22-4AP, TRPH-222CD22(null)Monoclonals10366Option to all assets related to TRPH-222 anti-CD22 antibody-drug conjugate for lymphoma
68
CancerImmuno-Oncology1355varlilumab, CDX-1127CD27InhibitorMonoclonals2671Phase I/II evaluation of nivolumab combined with varlilumab for cancer
69
CancerImmuno-Oncology1355varlilumab, CDX-1127CD27InhibitorMonoclonals2838Phase I evaluation of ONT-10 combined with varlilumab for breast and ovarian cancer
70
CancerImmuno-Oncology1355varlilumab, CDX-1127CD27InhibitorMonoclonals4871Phase I/II evaluation of varlilumab combined with MPDL3280A for renal cell carcinoma
71
CancerImmuno-Oncology1355varlilumab, CDX-1127CD27InhibitorMonoclonals9425Varlilumab, human antibodies towards CD27, for treatment of cancer
72
UnlimitedImmuno-Oncology1355varlilumab, CDX-1127CD27InhibitorMonoclonals31UltiMab technology including varlilumab (CD27 MAb)
73
CancerImmuno-Oncology221enoblituzumab, MGA271CD276 (B7-H3)InhibitorMonoclonals1572MGA271 (B7-H3-targeting Fc-MAb) for solid tumors Ex-NAFTA, Japan, S Korea & India
74
CancerImmuno-Oncology1119ES414, APVO414, MOR-209/ES-414CD3InhibitorMonoclonals3498ES414 (MOR209/ES414) bi-specific antibody for prostate cancer worldwide ex-US and Canada
75
CancerImmuno-Oncology1268GBR 1302CD3, epidermal growth factor receptor type 2 (HER2) (ERBB2) (receptor tyrosine-protein kinase erbB-2)(null)Monoclonals13448GBR 1302 HER2xCD3 bispecific antibody for HER2-positive cancers in China
76
CancerImmuno-Oncology215flotetuzumab, MGD006, S80880CD3, interleukin 3 (IL3) receptor alpha (CD123)InhibitorMonoclonals1577Flotetuzumab (MGD006 CD123) & MGD07 (gpA33) ex-NAFTA, Japan, S. Korea and India
77
CancerImmuno-Oncology53XmAb 14045CD3, interleukin 3 (IL3) receptor alpha (CD123)(null)Monoclonals9173XmAb 14045 (CD123/CD3) and XmAb 13676 (CD20/CD3 bispecific Fc MAb) ex-US
78
CancerImmuno-Oncology1391SGN-30, SGN30CD30InhibitorMonoclonals839SGN-30 Mab manufacture
79
CancerImmuno-Oncology1391SGN-30, SGN30CD30InhibitorMonoclonals853SGN15 & SGN30 Mab supply
80
CancerImmuno-Oncology731IMGN779CD33(null)Monoclonals11582IMGN779 (CD33) & IMGN632 (CD123) MAb conjugates for hematological malignancies
81
CancerImmuno-Oncology781MOR202, MOR03087CD38(null)Monoclonals1371MOR202 (fully human anti-CD38 monoclonal antibody) for multiple myeloma and leukemia
82
CancerImmuno-Oncology667Darzalex, daratumumab, JNJ-54767414, HuMax-CD38CD38InhibitorMonoclonals2364Daratumumab (HuMax-CD38) and backup human CD38 antibody for multiple myeloma
83
CancerImmuno-Oncology667Darzalex, daratumumab, JNJ-54767414, HuMax-CD38CD38InhibitorMonoclonals8467Phase 1b evaluation of daratumumab combined with atezolizumab for multiple myeloma and solid tumor
84
CancerImmuno-Oncology667Darzalex, daratumumab, JNJ-54767414, HuMax-CD38CD38InhibitorDiagnostics10293Hydrashift 2/4 daratumumab IVD reagent kit for use with Hydragel immunofixation test
85
CancerImmuno-Oncology667Darzalex, daratumumab, JNJ-54767414, HuMax-CD38CD38InhibitorDiagnostics11174NGS-based clonoSEQ Assay to assess minimal residual disease in Darzalex multiple myeloma trials
86
CancerImmuno-Oncology781MOR202, MOR03087CD38(null)Monoclonals12238MOR202 anti-CD38 mAb for multiple myeloma in China, Taiwan, Hong Kong and Macao
87
CancerImmuno-Oncology667Darzalex, daratumumab, JNJ-54767414, HuMax-CD38CD38InhibitorMonoclonals12397Supply of daratumumab to be evaluated with SY-1425 in leukemia & myelodysplastic syndrome
88
CancerImmuno-Oncology494IT1208CD4(null)Monoclonals8947IT1208 humanized anti-CD4 antibody for cancer
89
CancerImmuno-Oncology248zanolimumabCD4(null)Monoclonals10538Zanolimumab (HuMax­CD4) for T cell lymphoma, RA & psoriasis
90
CancerImmuno-Oncology391dacetuzumab, SGN-40, SGN-14, huS2C6, PRO 64553, RG 3636CD40InhibitorMonoclonals850SGN-14 (CD40 Mab) for cancer
91
CancerImmuno-Oncology391dacetuzumab, SGN-40, SGN-14, huS2C6, PRO 64553, RG 3636CD40InhibitorMonoclonals6529Dacetuzumab (SGN-40 anti-CD40 MAb) for cancer
92
CancerImmuno-Oncology309lucatumumab, HCD122, CHIR-12.12CD40(null)Monoclonals11377HCD122 (hu MAb to CD40) and X213 (hu MAb to Prolactin rec) for lymphoma & multiple myeloma
93
CancerImmuno-Oncology173Campath, alemtuzumab, LDP-03, MabCampath, Lemtrada, Campath-1HCD52InhibitorMonoclonals5902CAMPATH (alemtuzumab) humanized MAb for B-cell chronic lymphocytic leukemia ex-Asia
94
CancerImmuno-Oncology173Campath, alemtuzumab, LDP-03, MabCampath, Lemtrada, Campath-1HCD52InhibitorMonoclonals5903CAMPATH (alemtuzumab) humanized MAb for B-cell chronic lymphocytic leukemia in NA, EU & Japan
95
CancerImmuno-Oncology176lorvotuzumab mertansine, huN901-DM1, IMGN901, BB-10901CD56InhibitorMonoclonals1395huN901-DM1 tumor-activated prodrug for small-cell lung cancer in EU, EEA & Japan
96
CancerImmuno-Oncology176lorvotuzumab mertansine, huN901-DM1, IMGN901, BB-10901CD56InhibitorMonoclonals1400HuN901 humanized monoclonal antibody manufacture
97
CancerImmuno-Oncology1081ARGX-110CD70 (CD27L)(null)Monoclonals2400POTELLIGENT CHOK1SV cell line for use in development of ARGX-110 human mAb for CD70-positive tumors
98
CancerImmuno-Oncology1081ARGX-110CD70 (CD27L)(null)Monoclonals2994ARGX-110 anti-CD70 antibody for Waldenström’s macroglobulinemia
99
CancerImmuno-Oncology1081ARGX-110CD70 (CD27L)(null)Monoclonals6770ARGX-110 -based combination products for hematological malignancies
100
CancerImmuno-Oncology974HuMax-CD74CD74(null)Monoclonals3663Antibody-drug conjugate technology combined with Genmab’s HuMax-CD74 antibody
Loading...
Main menu